Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Holding OGN?
Track your performance easily
OGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.87 - $23.10
Previous Close$15.3
Volume4.45M
Average Volume (3M)2.68M
Market Cap
$3.94B
Enterprise Value$11.93B
Total Cash (Recent Filing)$763.00M
Total Debt (Recent Filing)$8.75B
Price to Earnings (P/E)3.0
Beta0.74
Next Earnings
Feb 13, 2025EPS Estimate
$0.93Last Dividend Ex-Date
Nov 12, 2024Dividend Yield7.32%
Share Statistics
EPS (TTM)5.04
Shares Outstanding257,538,875
10 Day Avg. Volume3,124,844
30 Day Avg. Volume2,680,561
Standard Deviation0.13
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)8.01
Price to Sales (P/S)0.61
Price to Cash Flow (P/CF)7.00
P/FCF Ratio4.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit3.18
Enterprise Value/Ebitda9.42
Forecast
1Y Price Target
$20.83Price Target Upside42.87% Upside
Rating ConsensusHold
Number of Analyst Covering7
Organon News
PremiumCompany Announcements
Organon’s VTAMA Cream FDA Review Extended to 2025
PremiumCompany Announcements
Organon & Co. Reports Strong Third Quarter 2024 Results
PremiumCompany Announcements
Organon Posts Strong Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Product ApprovalManagement noted that VTAMA AD approval could come a little early which could represent incremental product sales upside.
Product PerformanceNexplanon showed zero pregnancies in high BMI patients, which could raise the bar for generics, potentially exceeding $1.5bn in peak sales.
Strategic TransactionThe recent Dermavant transaction for VTAMA is expected to be accretive to EBITDA margin after 2025 with anticipated revenue acceleration.
Bears Say
EarningsEBITDA guidance was lowered mostly because of increased IPR&D expenses.
Financial PerformanceThe VTAMA deal requires additional spending to support initial launch, impacting EBITDA margin.
Market ConditionsThe key hurdle for VTAMA will be navigating a heavily managed category as the drug is not covered with 40% of plans and carries high gross-to-net deductions.
---
Ownership Overview
0.20% Insiders
22.22% Mutual Funds
19.68% Other Institutional Investors
32.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $12.87 and its highest was $23.10 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Feb 13, 2025 which is in 53 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on Oct 31, 2024. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.903 by -$0.033.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 7.32%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is $0.93.
How many shares outstanding does Organon have?
Organon has 257,538,880 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $0.87 in its last earnings report, missing expectations of $0.903. Following the earnings report the stock price went up 4.711%.
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 47M.
---
Organon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.83 (42.87% Upside)
$20.83 (42.87% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.80%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q3 2024
0:00 / 0:00
---
OGN Stock 12 Month Forecast
Average Price Target
$20.83
▲(42.87% Upside)
Technical Analysis
Heron Therapeutics
―
Supernus Pharmaceuticals
―
Perrigo Company
―
Pacira Pharmaceuticals
―
Best Analysts Covering OGN
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+9.34%
reiterated a sell rating 10 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +9.34% per trade.
---